Dynavax Technologies Corporation (DVAX)

Oncology Corporate Profile

Stock Performance

18.5300
-2.4500

HQ Location

2929 Seventh Street, Suite 100
Berkeley, CA 94710

Company Description

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine.

Website: http://www.dynavax.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SD-101 (+ anti PD-1)toll-like receptor 9 (TLR9)MelanomaI
SD-101 (+ anti PD-1)toll-like receptor 9 (TLR9)Squamous cell cancer of the head and neck (SCCHN)I
SD-101 (+ anti IL-10)toll-like receptor 9 (TLR9)Various cancer typesIMerck
DV281toll-like receptor 9 (TLR9)Various cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.dynavax.com/

Recent News Headlines

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/11/2017 12:17 pm

5/11/2017 12:17 pm

5/11/2017 12:17 pm

5/11/2017 12:17 pm

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/8/2017 12:17 am

5/8/2017 12:17 am

4/7/2017 12:17 pm

4/7/2017 12:17 pm

4/7/2017 06:17 am

4/7/2017 06:17 am

Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B

4/3/2017 10:00 am

[Marketwired] - Dynavax Technologies Corporation announced today that the U.S. Food and Drug Administration has informed the company that the Vaccines and Related Biological Products Advisory Committee will review HEPLISAV-B™......